<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24759">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784444</url>
  </required_header>
  <id_info>
    <org_study_id>MSDC-0602K-C009NASH</org_study_id>
    <nct_id>NCT02784444</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability &amp; Efficacy of MSDC 0602K in Patients With NASH</brief_title>
  <acronym>EMMINENCE</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octeta Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Octeta Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded study of three doses of MSDC-0602K (62.5, 125 and 250
      mg) or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and
      no cirrhosis. Subjects will be stratified by presence of T2DM (Yes/No), use of Vitamin E ≥
      400 IU (Yes/No) and fibrosis score (1 or ≥ 2) to ensure equal representation across all
      groups. The primary efficacy endpoint, hepatic histological improvement in NAS defined as a
      decrease of at least 2 points with no concurrent worsening of fibrosis stage,will be
      assessed at 12 months. Visits to the clinic will be at baseline, 1, 2, 3, 6, 9, and 12
      months, with one 2- week follow-up visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded study of three doses of MSDC-0602K (62.5, 125 and 250
      mg) or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and
      no cirrhosis. Subjects will be stratified by presence of T2DM (Yes/No), use of Vitamin E ≥
      400 IU (Yes/No) and fibrosis score (1 or ≥ 2) to ensure equal representation across all
      groups. The primary efficacy endpoint, as well as 5 secondary endpoints, will be assessed at
      12 months. Visits to the clinic will be at baseline, 1, 2, 3, 6, 9, and 12 months, with one
      2- week follow-up visit.

      Subjects with biopsy proven NASH (NAS ≥ 4; at least one point in each category) with F1 to
      F3 fibrosis score will be enrolled into the study. Subjects with demonstrated cirrhosis,
      hepatitis C, or excess alcohol consumption will be excluded from the trial. Females should
      be postmenopausal or surgically sterilized. Patients must have signed an informed consent.

      Approximately 200 subjects will be randomized with the intent to have 180 subjects complete
      the 12 month assessment (4 groups; approximately 45 subjects/group) at 37 sites in the US.
      Subjects who do not complete the study will not be replaced.

      Size #00 opaque gelatin capsules will be prepared using MSDC-0602K tablets or matching
      placebo capsules containing micro-crystalline cellulose. All doses will be taken orally with
      about 8 ounces (one glassful) of room temperature water at least 30 minutes before
      breakfast. Dose levels for MSDC-0602K will be 62.5mg, 125 mg, and 250 mg. Each patient will
      self-administer one capsule per day.

      This study will be comprised of a maximum 21-day Screening period, a treatment period of 360
      days and a 14-day follow-up period. The total duration of the study for each patient will be
      approximately 402 days, including follow-up.

      Safety will be assessed by periodic measurement of vital signs, 12 lead electrocardiogram
      (ECG), physical examinations and questions regarding potential adverse events (AEs). Fasting
      blood samples for clinical chemistries and hematology will be collected at each study visit
      (Screening and Study Visits 1-8). Samples for urinalysis will be collected at Screening and
      all Study Visits except Visits 2 and 3 (Days 1, 90, 180, 270 and 360).

      Blood samples for trough PK analysis of MSDC-0602 and MSDC 0597 (the hydroxymetabolite) will
      be taken at Study Visits 2, 4, 5, 6 and 7 (Days 30, 90, 180, 270 and 360).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic histological improvement in NASH defined as a decrease in the NAS (NASH CRN scoring) by at least 2 points with no concurrent worsening of fibrosis at 12 months</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>The reduction in NAS must include either a 1 point reduction in ballooning or inflammation. Worsening of fibrosis is evaluated using the NASH Clinical Research Network (CRN) fibrosis staging system and defined as progression of at least one stage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>12 months (360 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieve resolution of NASH by hepatic histology at 12 months.</measure>
    <time_frame>12 months (360 days)</time_frame>
    <description>Resolution of NASH is defined as a ballooning score of 0 and an inflammation score of 0-1 without worsening of fibrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieve an improvement in liver fibrosis, determined by a reduction from baseline of at least one point by NASH CRN scoring at 12 months.</measure>
    <time_frame>12 months (360 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in the NAFLD activity score and each one of its components (steatosis, inflammation and ballooning) at 12 months.</measure>
    <time_frame>12 months (360 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from baseline in fibrosis score (NASH CRN scoring) at 12 months.</measure>
    <time_frame>12 months (360 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>MSDC-0602K 62.5 mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSDC-0602K 62.5 mg capsules taken once daily for 360 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602K 125 mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSDC-0602K 125 mg capsules taken once daily for 360 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0602K 250 mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSDC-0602K 250 mg capsules taken once daily for 360 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo #00 capsules taken once daily for 360 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0602K</intervention_name>
    <description>(RS) 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione potassium</description>
    <arm_group_label>MSDC-0602K 62.5 mg capsules</arm_group_label>
    <arm_group_label>MSDC-0602K 125 mg capsules</arm_group_label>
    <arm_group_label>MSDC-0602K 250 mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Microcrystalline cellulose</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects between the ages of 18-75 years, inclusive.

          -  Histological evidence of NASH, based on biopsy, with a NAS (NASH CRN scoring) ≥ 4
             with a score of at least 1 in each component of NAS.

          -  Histological evidence of liver fibrosis defined as NASH CRN System Stage 1 to 3.

          -  Male and female subjects with NASH and a fibrosis score of F1 to F3 (NASH CRN
             scoring) with interpretable liver biopsy within 6 months prior to start of study. If
             no usable liver biopsy is available within 6 months prior to start of study, subjects
             must agree to have a liver biopsy performed at Screening for those eligible subjects
             who meet all other entry criteria. All eligible subjects must agree to have one liver
             biopsy at the end of study treatment (one year).

          -  If the subjects have type 2 diabetes, they must be under stable and reasonable
             control. Male and female subjects with reasonably controlled type 2 diabetes mellitus
             (DM) are defined as under physician's care for diabetes with glycosylated hemoglobin
             [HbA1c] ≤ 9.5%. If the subjects are taking permitted anti-diabetic therapies, they
             must be on stable doses of the following antidiabetics for a period of at least 3
             months prior to the diagnostic liver biopsy: metformin, GLP-1 agonists, SGLT2
             inhibitors, sulfonylureas, or DPP4 inhibitors. Refer to Section 4.3 for additional
             clarification about the use of antidiabetics.

          -  Male and female subjects who are taking Vitamin E should be on a stable dose of
             Vitamin E (if ≥ 400 IU) for a period of at least 3 months prior to the diagnostic
             liver biopsy.

          -  Females should be either postmenopausal (at least 12 months since last menses) or
             surgically sterilized (bilateral tubal ligation or hysterectomy). Menopausal status
             will be verified by a follicle-stimulating hormone (FSH) test. If FSH levels are
             below 40 mIU/mL, some method of birth control must be used. Those with bilateral
             tubal ligation must also use a barrier method of birth control. In addition, all
             females must have a negative pregnancy test at Screening and Day 1 regardless of
             childbearing potential. For postmenopausal women only, if FSH levels are above 40
             mIU/mL and serum pregnancy results are indeterminant, the subject will be assessed as
             not pregnant.

        Males with female partners of child-bearing potential must agree to use adequate
        contraceptive methods (including a condom, plus one other form of contraception) if
        engaging in sexual intercourse.

          -  Body Mass Index (BMI) &lt; 45 kg/m2.

          -  Willing and able to sign an informed consent document indicating understanding the
             purpose of and procedures required for the study and willingness to participate in
             the study.

          -  Willing and able to make a Screening visit to the clinic and eight visits over a 12.5
             month period.

        Exclusion Criteria:

          -  Known history of HIV.

          -  Prior liver transplantation.

          -  Other well-documented causes of active chronic liver disease, including, but not
             restricted to: history of positive hepatitis B surface antigen (HBsAg) or HCV RNA,
             suspicion of drug-induced liver disease, alcoholic liver disease and auto-immune
             hepatitis, Wilson's disease hemochromatosis, primary biliary cirrhosis, primary
             sclerosing cholangitis, genetic hemochromatosis, known or suspected HCC, history of
             planned liver transplant or current MELD score &gt;12. Subjects need to be viremia free
             for 2 years.

          -  History of cirrhosis and/or hepatic decompensation including ascites, hepatic
             encephalopathy or variceal bleeding. Platelet count &lt; 100,000/µL of blood.

          -  AST and ALT &gt; 160 U/L.

          -  Bilirubin &gt; 1.8 mg/dL and/or serum albumin &lt; 2.5 gms/dL.

          -  Impaired coagulation or PT/INR ≥ 1.5 times ULN.

          -  History of alcohol abuse or drug abuse within 6 months of Screening.

          -  Inability to safely obtain a liver biopsy.

          -  Type 1 diabetes mellitus.

          -  Use of ursodeoxycholic acid.

          -  Use of any diabetes medications other than metformin, GLP-1 agonists, SGLT2
             inhibitors, sulfonylureas, or DPP4 inhibitors three months prior to the baseline
             diagnostic liver biopsy or during the study unless as specified in the protocol. Use
             of insulin or PPARγ agonists (pioglitazone or rosiglitazone) are not allowed. Refer
             to Section 4.3 for additional clarification about the use of antidiabetics.

          -  Use of concomitant medications with a known significant metabolism by CYP2C8 or
             CPY2C9 including: paclitaxel, phenytoin, warfarin, celecoxib, tolbutamide, and
             replaglinide.

          -  History of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

          -  History of heart failure (including CHF) or previous cardiovascular event (myocardial
             infarct, by-pass surgery, or PTCA) within the past 6 months prior to Screening.

          -  Serum creatinine &gt;2 mg/dL.

          -  Current or recurrent disease that may affect the action, absorption or disposition of
             the study treatment, or clinical or laboratory assessments.

          -  Current or history of severe or unstable disorder (medical or psychiatric) requiring
             treatment that may make the patient unlikely to complete the study.

          -  Blood pressure greater than 160/100 mmHg. Patients with elevated BP (but &lt;160/100
             mmHg) with or without current treatment will be allowed at the discretion of the
             Investigator and primary care physician. Individuals with hypertension must have been
             stabilized to the current treatment regimen for at least 6 weeks prior to Screening.

          -  Known or suspected intolerance or hypersensitivity to the study drugs, closely
             related compounds or any of their stated ingredients.

          -  Have participated in an investigational study or received an investigational drug
             within 30 days or 5 half-lives (whichever is longer) prior to study drug
             administration.

          -  Blood donation of 1 pint or more within 56 days of Screening.

          -  Plasmapheresis or plasma donation within 30 days of Screening.

          -  Single 12-lead ECG demonstrating a QTcB &gt;450 msec at Screening. A single repeat ECG
             may be done at the Investigator's discretion.

          -  Any surgical or medical condition which may significantly alter the absorption of any
             drug substance including, but not limited to, any of the following: history of major
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel
             resection, gastric bypass, gastric stapling, or gastric banding, currently active
             inflammatory bowel syndrome.

          -  Evidence of clinically relevant pathology that could interfere with the study results
             or put the patient's safety at risk.

          -  Malignancy, including leukemia and lymphoma (not including basal cell skin cancer)
             not treated within the last 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R Colca, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Octeta Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jay Yockelson, MS</last_name>
    <phone>984-227-3476</phone>
    <email>jay.yockelson@covance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Cavaliere, MS</last_name>
    <phone>484-502-9903</phone>
    <email>linda.cavaliere@covance.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>G W Research Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Glincosky, PA-C</last_name>
    </contact>
    <contact_backup>
      <last_name>Arturo A Armendariz, PA-C</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gregory J Wiener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reuben Farris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerome Glincosky, PC-A</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arturo A Armendariz, PC-A</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Clinical Research, Inc</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ban Doon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Dao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ban Doon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison McManus, DPN, FNP-BC</last_name>
    </contact>
    <investigator>
      <last_name>J. Scott Overcash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carrie Cardenas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon DeVita, CPNP-PC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parul Desai, NP</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axis ClinicalTrials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parul Desari, NP</last_name>
    </contact>
    <investigator>
      <last_name>Lydie Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Bradshaw, PA</last_name>
    </contact>
    <investigator>
      <last_name>Kevin Mertes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cory Amador, PA</last_name>
    </contact>
    <contact_backup>
      <last_name>Yvonne Hu, NP</last_name>
    </contact_backup>
    <investigator>
      <last_name>Zeid Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cory Amador, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Hu, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa M Richards, PNP-BC</last_name>
    </contact>
    <contact_backup>
      <last_name>Emily S Rizo, MSN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rohit Loomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa M Richards, PNP-BC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily S Rizo, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrocare Research, LLC d/b/a DigestiveCARE Research</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Health-Clinical and Translational Research Building</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Cusi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Cusi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio Leey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Dayton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Barb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauri Dhir, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Bril</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvette Trahan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Lo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dana Mills</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginia Clark, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Firpi-Morell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vida Medical Research, Inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Palmetto Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Auda</last_name>
    </contact>
    <investigator>
      <last_name>Jeff Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharth Mathus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul A Hellstern, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siddharth Mathus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Ricardo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier R Colomar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vista Health Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clay Wexler, ARNP</last_name>
    </contact>
    <contact_backup>
      <last_name>Miguel Perez-Martinez, ARNP</last_name>
    </contact_backup>
    <investigator>
      <last_name>Antonio Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernesto Rodriguez-Valdes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Lopez, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clay Wexler, ARPN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Perez-Martinez, ARPN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Center for Gastroenterology</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew J Smith, DO</last_name>
    </contact>
    <contact_backup>
      <last_name>Steven R Sacks, DO</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mitchell M Davis, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew J Smith, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven R Sacks, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialist of Georgia, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Platt, BS</last_name>
    </contact>
    <contact_backup>
      <last_name>September A Wayne</last_name>
    </contact_backup>
    <investigator>
      <last_name>Aasim M Sheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raja Sappati Biyyani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suku George, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madhuri Meka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Kommor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Platt, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>September A Wayne</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samer Gawrieh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samer Gawrieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naga Chalassani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marwin Ghabril, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Lemmert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Orman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niharika Samala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Masuoka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners, LLC</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa McCullars, RN, CCRC</last_name>
    </contact>
    <investigator>
      <last_name>Bal R Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry H Hinkle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine LACaTS Clinical Translational Unit</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Nola Research Works</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Royes, NP</last_name>
    </contact>
    <investigator>
      <last_name>Vivek Huilgol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nell Wolfson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Wells, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Royes, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates PA</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Rodriguez, PA-C</last_name>
    </contact>
    <investigator>
      <last_name>Duane Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Rodriguez, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, Inc</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>ID Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>112301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebone LeGall, PA</last_name>
    </contact>
    <investigator>
      <last_name>Tiffany Marum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ebone LaGall, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Weissbrod, PA</last_name>
    </contact>
    <investigator>
      <last_name>Scott Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Weissbrod, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ebone LeGall, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Locklear, PA</last_name>
    </contact>
    <contact_backup>
      <last_name>Brittany Morris, PA</last_name>
    </contact_backup>
    <investigator>
      <last_name>Valli Kodali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Poulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arvind Kumar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Daniels, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Henderson, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jill Rys, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Digestive Diseases, PA</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Goldstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Phillip Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Center for Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya L Williams, PA-C</last_name>
    </contact>
    <investigator>
      <last_name>Robert W Reindollar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Gastroenterology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Newton, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Sepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Newton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josetta Swearingen, CCRC</last_name>
    </contact>
    <contact_backup>
      <last_name>Melissa L Horton, CCRC</last_name>
    </contact_backup>
    <investigator>
      <last_name>Reem H Ghalib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tarek Al-Assi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheryl D Levine, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josetta Swearingen, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa L Horton, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hope Villegas, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Young, APRN</last_name>
    </contact>
    <contact_backup>
      <last_name>Milka Ndungu, APRN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Msidha Barnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parvez Mantry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adil Habib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mangesh Pagadala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hector Nazario, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aden Tadelle, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Teachenor, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Young, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milka Ndungu, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Humberto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angelo Humberto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna G Marowske, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine K Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Induruwa N Pathirana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amilcar M Cardona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Zela, RN</last_name>
    </contact>
    <investigator>
      <last_name>Victor Ankoma-Sey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chukwuma Egwim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Zela, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie H Kiser, MSN</last_name>
    </contact>
    <investigator>
      <last_name>Hays Arnold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Jones, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Harrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Membreno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Connie H Kiser, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahnoor Ali, PA-C</last_name>
    </contact>
    <investigator>
      <last_name>Fred Poordad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Ganeshappa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bijo John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Ganeshappa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Harrison, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Sterling, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Velimir Luketic, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Arun Sanyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Sterling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Velimir Luketic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>May 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
